Pulmonary hypertension caused by lung cancer suspected to have pulmonary tumor thrombotic microangiopathy and which we treated with gefitinib

Japanese Journal of Lung Cancer

Volumn 52, Issue 4, 2012, Pages 420-425

  Yoshinoya, Kiyokazu ^a   Kasamatsu, Yu ^a   Boku, Shougen ^a   Kida, Takashi ^a   Kadoya, Masatoshi ^a   Kasamatsu, Yoshihiro ^a  

^a MATSUSHITA MEMORIAL HOSPITAL   (Japan)

Author keywords

Epidermal growth factor receptor; Gefitinib; Pulmonary hypertension; Pulmonary tumor thrombotic microangiopathy

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB;

ADULT; ARTICLE; CASE REPORT; EXON; FEMALE; GENE DELETION; HUMAN; LUNG ADENOCARCINOMA; LUNG PARENCHYMA; LUNG TUMOR; MUTATIONAL ANALYSIS; PULMONARY HYPERTENSION; PULMONARY TUMOR THROMBOTIC MICROANGIOPATHY; THROMBOTIC THROMBOCYTOPENIC PURPURA;

EID: 84867090006     PISSN: 03869628     EISSN: None     Source Type: Journal    
DOI: 10.2482/haigan.52.420     Document Type: Article

References (10)

1. Chinen K, Tokuda Y, Fujiwara M, Fujioka Y. Pulmonary tumor thrombotic microangiopathy in patients with gastric carcinoma: an analysis of 6 autopsy cases and review of the literature. Pathol Res Pract. 2010;206:682-689.
2. Miyano S, Izumi S, Takeda Y, Tokuhara M, Mochizuki M, Matsubara O, et al. Pulmonary tumor thrombotic microangiopathy. J Clin Oncol. 2007;25:597-599. (Pubitemid 350002969)
3. Uruga H, Morokawa N, Enomoto T, Takaya H, Miyamoto A, Kishi K, et al. A case of pulmonary tumor thrombotic microangiopathy associated with lung adenocarcinoma diagnosed by CT-guided lung biopsy. Nihon Kokyuki Gakkai Zasshi. 2008;46:928-933.
4. Noguchi S, Imanaga T, Shimizu M, Nakano T, Miyazaki N. Case of pulmonary tumor thrombotic microangiopathy diagnosed by transbronchial lung biopsy. Nihon Kokyuki Gakkai Zasshi. 2008;46:493-496.
5. von Herbay A, Illes A, Waldherr R, Otto HF. Pulmonary tumor thrombotic microangiopathy with pulmonary hypertension. Cancer. 1990;66:587-592. (Pubitemid 20233461)
6. Janda S, Shahidi N, Gin K, Swiston J. Diagnostic accuracy of echocardiography for pulmonary hypertension: a systematic review and meta-analysis. Heart. 2011;97:612-622.
7. Mitsudomi T, Yatabe Y. Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer. Cancer Sci. 2007;98:1817-1824. (Pubitemid 350002184)
8. Chan AK, Kalmes A, Hawkins S, Daum G, Clowes AW. Blockade of the epidermal growth factor receptor decreases intimal hyperplasia in balloon-injured rat carotid artery. J Vasc Surg. 2003;37:644-649. (Pubitemid 36350912)
9. Dahal BK, Cornitescu T, Tretyn A, Pullamsetti SS, Kosanovic D, Dumitrascu R, et al. Role of epidermal growth factor inhibition in experimental pulmonary hypertension. Am J Respir Crit Care Med. 2010;181:158-167.
10. Cufer T, Vrdoljak E, Gaafar R, Erensoy I, Pemberton K, SIGN Study Group. Phase II, open-label, randomized study (SIGN) of single-agent gefitinib (IRESSA) or docetaxel as second-line therapy in patients with advanced (stage IIIb or IV) non-small-cell lung cancer. Anticancer Drugs. 2006;17:401-409. (Pubitemid 44309982)